Targeting mutant KRAS with CRISPR-Cas9 controls tumor growth

KRAS is the most frequently mutated oncogene in human tumors, and its activating mutations represent important therapeutic targets. The combination of Cas9 and guide RNA from the CRISPR-Cas system recognizes a specific DNA sequence and makes a double-strand break, which enables editing of the releva...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Genome Res
Main Authors: Kim, Wonjoo, Lee, Sangeun, Kim, Han Sang, Song, Minjung, Cha, Yong Hoon, Kim, Young-Hoon, Shin, Jeonghong, Lee, Eun-Seo, Joo, Yeonsoo, Song, Jae J., Choi, Eun Ju, Choi, Jae W., Lee, Jinu, Kang, Moonkyung, Yook, Jong In, Lee, Min Goo, Kim, Yeon-Soo, Paik, Soonmyung, Kim, Hyongbum (Henry)
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory Press 2018
Assuntos:
Method
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5848616/
https://ncbi.nlm.nih.gov/pubmed/29326299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gr.223891.117
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados